A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System.

Paz-Ares, L

A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System. [electronic resource] - Journal of clinical pharmacy and therapeutics Aug 2010 - 429-38 p. digital

Publication Type: Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

1365-2710

10.1111/j.1365-2710.2009.01135.x doi


Angiogenesis Inhibitors--administration & dosage
Carcinoma, Renal Cell--drug therapy
Cost-Benefit Analysis
Cytokines--therapeutic use
Disease Progression
Disease-Free Survival
Drug Costs
Drug Resistance, Neoplasm
Female
Health Care Costs
Humans
Immunotherapy
Indoles--administration & dosage
Kidney Neoplasms--drug therapy
Male
Markov Chains
Middle Aged
Models, Economic
Palliative Care--economics
Protein Kinase Inhibitors--administration & dosage
Pyrroles--administration & dosage
Quality-Adjusted Life Years
Spain
Sunitinib